Hepatitis B-related glomerulonephritis and optimization of treatment

References

• Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–1555.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012 Mar 9;30(12):2212–2219.
   PubMed Web of Science ®Google Scholar
• Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018 Jan;38(1):23–32.
   PubMed Web of Science ®Google Scholar
• Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet. 1971 Jul 31;2(7718):234–237.
   PubMed Web of Science ®Google Scholar
• Levy M, Chen N. Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int Suppl. 1991 Dec;35:S24–33.
   PubMedGoogle Scholar
• Zhang Y, Fang L, Ma X. Hepatitis B virus infection and pathogenesis of glomerulonephritis. Zhonghua Bing Li Xue Za Zhi. 1995 Dec;24(6):341–344.
   PubMedGoogle Scholar
• Zhao W, Ma Y, Wang M, et al. Expression of Foxp3 in renal tissue of patients with HBV-associated glomerulonephritis and their clinical and pathological characteristics. Exp Ther Med. 2017 Nov;14(5):4928–4934.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Saadoun D, Bourliere M, et al. Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol. 2005 Nov;43(5):764–770.
   PubMed Web of Science ®Google Scholar
• Chan TM. Hepatitis B and renal disease. Curr Hepat Rep. 2010 May;9(2):99–105.
   PubMedGoogle Scholar
• Kupin WL. Viral-Associated GN: hepatitis B and other viral infections. Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1529–1533.
   PubMed Web of Science ®Google Scholar
• Kusakabe A, Tanaka Y, Kurbanov F, et al. Virological features of hepatitis B virus-associated nephropathy in Japan. J Med Virol. 2007 Sep;79(9):1305–1311.
   PubMed Web of Science ®Google Scholar
• Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):249–255.
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int. 1990;37(2):663–676.
   PubMed Web of Science ®Google Scholar
• Gupta A, Quigg RJ. Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis. 2015 Sep;22(5):343–351.
   PubMed Web of Science ®Google Scholar
• He XY, Fang LJ, Zhang YE, et al. In situ hybridization of hepatitis B DNA in hepatitis B-associated glomerulonephritis. Pediatr Nephrol. 1998 Feb;12(2):117–120.
   PubMed Web of Science ®Google Scholar
• Diao Z, Ding J, Yin C, et al. Purified hepatitis B virus induces human mesangial cell proliferation and extracellular matrix expression in vitro. Virol J. 2013 Oct ;04(10):300.
   Google Scholar
• Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. Southwest pediatric nephrology study group. J Pediatr. 1985 Apr;106(4):571–578.
   PubMedGoogle Scholar
• Wiggelinkhuizen J, Sinclair-Smith C, Stannard LM, et al. B virus associated membranous glomerulonephritis. Arch Dischildhood. 1983 Jul;58(7):488–496.
   PubMed Web of Science ®Google Scholar
• Li P, Wei RB, Tang L, et al. Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Clin Nephrol. 2012 Dec;78(6):456–464.
   PubMed Web of Science ®Google Scholar
• Lee HS, Choi Y, Yu SH, et al. A renal biopsy study of hepatitis B virus-associated nephropathy in Korea. Kidney Int. 1988 Oct;34(4):537–543.
   PubMed Web of Science ®Google Scholar
• Collins AB, Bhan AK, Dienstag JL, et al. Hepatitis B immune complex glomerulonephritis: simultaneous glomerular deposition of hepatitis B surface and e antigens. Clin Immunol Immunopathol. 1983 Jan;26(1):137–153.
   PubMedGoogle Scholar
• Xie Q, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol. 2015;41(4–5):345–353.
   PubMed Web of Science ®Google Scholar
• Qin W, Beck LH, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011 Jun;22(6):1137–1143.
   PubMed Web of Science ®Google Scholar
• Takekoshi Y, Tanaka M, Shida N, et al. Strong association between membranous nephropathy and hepatitis-B surface antigenaemia in Japanese children. Lancet. 1978 Nov 18;2(8099):1065–1068.
   PubMed Web of Science ®Google Scholar
• Ozdamar SO, Gucer S, Tinaztepe K. Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children. Pediatr Nephrol. 2003 Jan;18(1):23–28.
   PubMed Web of Science ®Google Scholar
• Hsu HC, Wu CY, Lin CY, et al. Membranous nephropathy in 52 hepatitis B surface antigen (HBsAg) carrier children in Taiwan. Kidney Int. 1989 Dec;36(6):1103–1107.
   PubMed Web of Science ®Google Scholar
• Lu Y, Shen P, Li X, et al. Re-evaluation of the classification system for membranoproliferative glomerulonephritis. Contrib Nephrol. 2013;181:175–184.
   PubMed Web of Science ®Google Scholar
• Li SJ, Xu ST, Chen HP, et al. Clinical and morphologic spectrum of renal involvement in patients with HBV-associated cryoglobulinaemia. Nephrology. 2017 Jun;22(6):449–455.
   PubMed Web of Science ®Google Scholar
• Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004 Mar-Apr;24(2):198–211.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akimoto T, Okuda K, et al. Purpura with ulcerative skin lesions and mixed cryoglobulinemia in a quiescent hepatitis B virus carrier. Intern Med. 2014;53(2):115–119.
   PubMed Web of Science ®Google Scholar
• Lai KN, Lai FM, Chan KW, et al. The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. Q J Med. 1987 Apr;63(240):323–333.
   PubMedGoogle Scholar
• Nagy J, Bajtai G, Brasch H, et al. The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies. Clin Nephrol. 1979 Sep;12(3):109–116.
   PubMed Web of Science ®Google Scholar
• Slusarczyk J, Michalak T, Nazarewicz-de Mezer T, et al. Membranous glomerulopathy associated with hepatitis B core antigen immune complexes in children. Am J Pathol. 1980 Jan;98(1):29–43.
   PubMed Web of Science ®Google Scholar
• Lai KN, Lai FM, Lo S, et al. IgA nephropathy associated with hepatitis B virus antigenemia. Nephron. 1987;47(2):141–143.
   PubMed Web of Science ®Google Scholar
• Sakai K, Morito N, Usui J, et al. Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection. Nephrol Dialysis Trans. 2011 Jan;26(1):371–373.
   PubMed Web of Science ®Google Scholar
• Zhou TB, Jiang ZP. Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report. Ren Fail. 2015 Apr;37(3):459–461.
   PubMed Web of Science ®Google Scholar
• Kleinknecht C, Levy M, Peix A, et al. Membranous glomerulonephritis and hepatitis B surface antigen in children. J Pediatr. 1979 Dec;95(6):946–952.
   PubMed Web of Science ®Google Scholar
• Zhang Y. Treatment of hepatitis B virus-associated glomerulonephritis: A meta-analysis. World J Gastroenterol. 2010;16:6.
   Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006 Sep 01;24(5):781–788.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines–application to the individual patient. Kidney Int. 2012 Oct;82(8):840–856.
   PubMed Web of Science ®Google Scholar
• Al-Wakeel J, Mitwalli A, Tarif N, et al. Role of interferon-alpha in the treatment of primary glomerulonephritis. Am J Kidney Dis. 1999 Jun;33(6):1142–1146.
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003 Jul;10(4):298–305.
   PubMed Web of Science ®Google Scholar
• Wirth S, Zhang H, Hardikar W, et al. Efficacy and safety of peginterferon Alfa-2a (40KD) in children with chronic hepatitis B: the PEG-B-ACTIVE study. Hepatology. 2018 11;68(5):1681–1694.
   PubMed Web of Science ®Google Scholar
• Elewa U, Sandri AM, Kim WR, et al. Treatment of hepatitis B virus-associated nephropathy. Nephron Clin Pract. 2011;119(1):c41-9; discussion c49.
   Google Scholar
• Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int. 1995 Jan;47(1):225–230.
   PubMed Web of Science ®Google Scholar
• Lopes Neto EP, Lopes LV, Kirsztajn GM, et al. alpha-Interferon therapy for HBV-related glomerulonephritis. São Paulo Med J. 1998 Sep-Oct;116(5):1823–1825.
   PubMedGoogle Scholar
• Garcia G, Scullard G, Smith C, et al. Preliminary observation of hepatitis B-associated membranous glomerulonephritis treated with leukocyte interferon. Hepatology. 1985 Mar-Apr;5(2):317–320.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Kanai K, Matsuda H, et al. Improvement of proteinuria in a case of hepatitis B-associated glomerulonephritis after treatment with interferon. Gastroenterology. 1987 Feb;92(2):524–526.
   PubMed Web of Science ®Google Scholar
• Lisker-Melman M, Webb D, Di Bisceglie AM, et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann Intern Med. 1989 Sep 15;111(6):479–483.
   PubMed Web of Science ®Google Scholar
• Shah HH, Patel C, Jhaveri KD. Complete remission of hepatitis B virus-associated nephrotic syndrome from IgA nephropathy following peginterferon therapy. Ren Fail. 2013;35(2):295–298.
   PubMed Web of Science ®Google Scholar
• Chung DR, Yang WS, Kim SB, et al. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. Am J Nephrol. 1997;17(2):112–117.
   PubMed Web of Science ®Google Scholar
• Hsu HY, Tsai HY, Wu TC, et al. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int. 2008 Nov;28(9):1288–1297.
   PubMed Web of Science ®Google Scholar
• Lai MW, Chang MH. Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1065–1076.
   PubMed Web of Science ®Google Scholar
• Sun IO, Hong YA, Park HS, et al. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med. 2012 Dec;27(4):411–416.
   PubMed Web of Science ®Google Scholar
• Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int. 2005 Oct;68(4):1750–1758.
   PubMed Web of Science ®Google Scholar
• Connor FL, Rosenberg AR, Kennedy SE, et al. HBV associated nephrotic syndrome: resolution with oral lamivudine. Arch Dis Child. 2003 May;88(5):446–449.
   PubMed Web of Science ®Google Scholar
• Lingala S, Lau DT, Koh C, et al. Long-term lamivudine therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016 Aug;44(4):380–389.
   PubMed Web of Science ®Google Scholar
• Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000 Oct;32(4 Pt 1):828–834.
   PubMedGoogle Scholar
• Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009 Nov;137(5):1593–608.e1-2.
   PubMed Web of Science ®Google Scholar
• Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996 Sep;24(3):714–717.
   PubMed Web of Science ®Google Scholar
• Park SH, Park KS, Kim NH, et al. Clevudine induced mitochondrial myopathy. J Korean Med Sci. 2017 Nov;32(11):1857–1860.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine study group. Gastroenterology. 2000 Jul;119(1):172–180.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol. 2011 Jan;26(Suppl 1):138–143.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Shimizu A, Igarashi T, et al. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy. J Nippon Med Sch. 2013;80(5):387–395.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Mochizuki T, Akihisa T, et al. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report. Medicine (Baltimore). 2019 Jan;98(2):e14014.
   PubMed Web of Science ®Google Scholar
• Mahajan V, D’Cruz S, Nada R, et al. Successful use of entecavir in hepatitis b-associated membranous nephropathy. J Trop Pediatr. 2018 Jun 1; 64(3):249–252.
   PubMed Web of Science ®Google Scholar
• Yang YF, Xiong QF, Zhao W, et al. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. Clin Res Hepatol Gastroenterol. 2012 Oct;36(5):e89–92.
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006 Mar 09;354(10):1001–1010.
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 09;354(10):1011–1020.
   PubMed Web of Science ®Google Scholar
• Lian JS, Zhang XL, Lu YF, et al. Switching lamivudine with adefovir dipivoxil combination therapy to entecavir monotherapy provides better viral suppression and kidney safety. Int J Med Sci. 2019;16(1):17–22.
   PubMed Web of Science ®Google Scholar
• Wu IT, Hu TH, Hung CH, et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect. 2017 Jul;23(7):464–469.
   PubMed Web of Science ®Google Scholar
• Han Y, Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol. 2017;42:168–175.
   PubMed Web of Science ®Google Scholar
• Shi H, Huang M, Lin G, et al. Efficacy comparison of tenofovir and entecavir in hbeag-positive chronic hepatitis b patients with high HBV DNA. Biomed Res Int. 2016;2016:6725073.
   PubMedGoogle Scholar
• Shi H, Han Z, Liu J, et al. Comparing efficacy of lamivudine, adefovir dipivoxil, telbivudine, and entecavir in treating nucleoside analogues naïve for HBeAg-negative hepatitis b with medium hepatitis b virus (HBV) DNA levels. Med Sci Monit. 2017 Nov;02(23):5230–5236.
   Google Scholar
• Lampertico P, Chan HL, Janssen HL, et al. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016 07;44(1):16–34.
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009 Dec;50(6):2001–2006.
   PubMed Web of Science ®Google Scholar
• Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011 Oct;141(4):1212–1219.
   PubMed Web of Science ®Google Scholar
• Noble J, Jouve T, Malvezzi P, et al. Renal complications of liver diseases. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1135–1142.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808–816.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008 Sep;48(3):750–758.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):800–807.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2673–2681.
   PubMed Web of Science ®Google Scholar
• Fung J, Seto WK, Lai CL, et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014 Mar;29(3):428–434.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004 Sep;66(3):1153–1158.
   PubMed Web of Science ®Google Scholar
• EASL. clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167–185.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009 Feb;136(2):486–495.
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007 Dec 20;357(25):2576–2588.
   PubMed Web of Science ®Google Scholar
• Fung J, Seto WK, Lai CL, et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014 Mar;29(3):428–434.
   PubMed Web of Science ®Google Scholar
• Shen Y, Jia Y, Zhou J, et al. Bayesian network meta-analysis for assessing adverse effects of anti-hepatitis B drugs. Clin Drug Investig. 2019 Sep;39(9):835–846.
   Web of Science ®Google Scholar
• Govan L, Wu O, Xin Y, et al. Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis. Eur J Gastroenterol Hepatol. 2015 Aug;27(8):882–894.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 04;359(23):2442–2455.
   PubMed Web of Science ®Google Scholar
• Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol. 2017 Nov;11(11):999–1008.
   PubMed Web of Science ®Google Scholar
• Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 04;68(4):672–681.
   PubMed Web of Science ®Google Scholar
• Viganò M, Loglio A, Grossi G, et al. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Rev Anti Infect Ther. 2018 02;16(2):153–161.
   PubMed Web of Science ®Google Scholar
• Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015 Mar;62(3):533–540.
   PubMed Web of Science ®Google Scholar
• Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol. 1994 Feb;8(1):11–14.
   PubMed Web of Science ®Google Scholar
• Bhimma R, Coovadia HM, Kramvis A, et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol. 2002 Jun;17(6):393–399.
   PubMed Web of Science ®Google Scholar
• Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet. 2003 Dec 20;362(9401):2089–2094.
   PubMed Web of Science ®Google Scholar
• Lai KN, Tam JS, Lin HJ, et al. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron. 1990;54(1):12–17.
   PubMed Web of Science ®Google Scholar
• Cadrobbi P, Bortolotti F, Zacchello G, et al. Hepatitis B virus replication in acute glomerulonephritis with chronic active hepatitis. Arch Dis Child. 1985 Jun;60(6):583–585.
   PubMed Web of Science ®Google Scholar
• Lai FM, Tam JS, Li PK, et al. Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy. Virchows Arch A. 1989;414(3):279–284.
   Web of Science ®Google Scholar
• Taskapan H, Oymak O, Dogukan A, et al. Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form. Clin Nephrol. 2000 Aug;54(2):161–163.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Davis GL, Pappas SC, et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1986 Jan;104(1):12–17.
   PubMed Web of Science ®Google Scholar
• Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011 May;22(5):1170–1180.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang J, Xu W, et al. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis. Onkologie. 2010;33(10):537–539.
   PubMedGoogle Scholar
• Hamada T, Kumashiro R, Koga Y, et al. Fatal acute hepatitis B virus infection while receiving immunosuppressants after renal transplantation. Intern Med. 1993 Jul;32(7):547–551.
   PubMed Web of Science ®Google Scholar
• Lai MK, Huang CC, Chu SH, et al. Renal transplantation in hepatitis B carriers: comparison of azathioprine- and cyclosporine-treated recipients. Clin Transplants. 1989;281–286.
   PubMedGoogle Scholar
• Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apheresis Dialysis. 2003 Apr;7(2):155–160.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Jarrousse B, et al. Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. Ann Med Interne. 1992;143(Suppl 1):63–74.
   PubMedGoogle Scholar